499
Participants
Start Date
May 31, 2012
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
Androxal
Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
IRC Clinics, Towson
East Coast Institute for Clinical Research, Jacksonville
East Coast Institute for Research, Jacksonville
East Coast Institute for Research, Jacksonville
Well Pharma Medical Research, Miami
Cetero Research, Miami Gardens
Therafirst Medical Center, Fort Lauderdale
Ebon Bourne, MD, Plantation
Meridien Research, St. Petersburg
Florida Fertility Institute, Clearwater
DMI Research, Pinellas Park
Meridien Research, Bradenton
Baptist Health Center for Clinical Research, Little Rock
Advances in Health, Houston
Breco Research, Sugar Land
Center of Reproductive Medicine, Webster
Clinical Research Advantage, Colorado Springs
Clinical Research Advantage, Colorado Springs
Lone Peak Family Medicine, Draper
Granger Medical Clin ic, Riverton
Clinical Research Advantage, Phoenix
Clinical Research Advantage, Glendale
Anthony Mills, MD, Los Angeles
West Coast Clinical Research, Tarzana
Catalina Research Institute, Chino
SD Uro-Research, San Diego
San Diego Sexual Medicine, San Diego
South Orange County Endocrinology, Laguna Hills
SC Clinical Research, Santa Ana
SC Clinical Research, Garden Grove
Premier Urology Associates, Lawrenceville
Repros Therapeutics Inc.
INDUSTRY